Aissatou B K T Ndiaye, Ibrahim Mohamed, Etienne Pronovost, Georgina Angoa, Bruno Piedboeuf, Brigitte Lemyre, Jehier Afifi, Mosarrat Qureshi, Thibaut Sériès, Mireille Guillot, David Simonyan, Kamran Yusuf, Pascal M Lavoie, William D Fraser, Benoît Mâsse, Anne Monique Nuyt, Thierry Lacaze-Masmonteil, Isabelle Marc
BACKGROUND: We aim to assess whether the docosahexaenoic acid (DHA)-containing lipid emulsion (LE) SMOFlipid 20% (Fresenius Kabi Canada Ltd) is associated with bronchopulmonary dysplasia (BPD)-free survival at 36 weeks' postmenstrual age in very preterm infants. METHODS: This cohort study is nested in the MOBYDIck randomized clinical trial (NCT02371460), which investigated the effect of maternal DHA supplementation on BPD-free survival in breastfed very preterm infants born between 23 0/7 and 28 6/7 weeks' gestation in 16 Canadian neonatal intensive care units (2015-2018)...
April 11, 2022: JPEN. Journal of Parenteral and Enteral Nutrition